Proof of Concept Pilot Study to Assess the Utility of Magnetic Resonance Extra-cellular Volume Quantification to Diagnose Advanced Liver Disease in People with Cystic Fibrosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2025 Mar 4

PMID 40036270

Authors

Daniel H Tewkesbury

Jennifer A Scott

Rowland J Bright-Thomas

Sue Liong

Josephine Naish

Velauthan Rudralingam

Karen Piper Hanley

Andrew M Jones

Varinder S Athwal

Affiliations

Soon will be listed here.

Abstract

Background: Current diagnostic tools are limited in their ability to diagnose cystic fibrosis liver disease (CFLD) as disease is often focal in nature. Magnetic resonance extracellular volume quantification (MRI ECV) in the liver may have diagnostic utility in CFLD as a more selective liver volume is assessed and can be performed using equipment readily available in clinical practice on a standard MRI protocol.

Methods: Healthy volunteers (HV), CF participants with no liver disease (CF-noLD) and CF participants with cirrhosis (CF-C) aged 18 years and above had MRI ECV measured using a 3T Siemens scanner. An additional retrospective analysis was performed to calculate MRI ECV in individuals who had available images obtained using a 1.5T Siemens scanner from a previous study.

Results: 16 individuals had MRI ECV measured using a 3T Siemens scanner. Mean (SD) MRI ECV was 0.316 (0.058) for HV (n = 5), 0.297 (0.034) for CF-noLD (n = 5) and 0.388 (0.067) for CF-C (n = 6 ). Post-hoc analysis showed a significant difference between CF-noLD and CF-C (p = 0.046). Of 18 individuals with available images using a 1.5T scanner, mean (SD) MRI ECV was 0.269 (0.048) in HV (n = 8), 0.310 (0.037) in CF-noLD (n = 8) and 0.362 (0.063) in CF-C (n = 2).

Conclusions: Liver MRI ECV quantification was feasible in adults with CF with no significant difference in results between 1.5T and 3T obtained images suggesting applicability across different types of MRI scanner. A higher MRI ECV was demonstrated in CF participants with cirrhosis suggesting potential utility as a diagnostic tool for those with advanced CFLD. Further evaluation in larger cohorts is warranted.

References

Scott J, Jones A, Piper Hanley K, Athwal V . Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther. 2022; 55(4):389-400. DOI: 10.1111/apt.16749. View

Dana J, Girard M, Debray D . Hepatic manifestations of cystic fibrosis. Curr Opin Gastroenterol. 2020; 36(3):192-198. DOI: 10.1097/MOG.0000000000000624. View

Haaf P, Garg P, Messroghli D, Broadbent D, Greenwood J, Plein S . Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016; 18(1):89. PMC: 5129251. DOI: 10.1186/s12968-016-0308-4. View

Lewindon P, Shepherd R, Walsh M, Greer R, Williamson R, Pereira T . Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology. 2011; 53(1):193-201. DOI: 10.1002/hep.24014. View

Cipolli M, Fethney J, Waters D, Zanolla L, Meneghelli I, Dutt S . Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study. J Cyst Fibros. 2019; 19(3):455-459. DOI: 10.1016/j.jcf.2019.09.016. View

Flass T, Narkewicz M . Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2012; 12(2):116-24. PMC: 3883947. DOI: 10.1016/j.jcf.2012.11.010. View

Tang A, Cloutier G, Szeverenyi N, Sirlin C . Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 2, Diagnostic Performance, Confounders, and Future Directions. AJR Am J Roentgenol. 2015; 205(1):33-40. PMC: 4803476. DOI: 10.2214/AJR.15.14553. View

Athwal V, Scott J, Fitzpatrick E, Rowland M . Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med. 2021; 27(6):593-599. DOI: 10.1097/MCP.0000000000000824. View

Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner D . Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017; 66(2):591-601. PMC: 5519421. DOI: 10.1002/hep.29217. View

10.

Ugander M, Oki A, Hsu L, Kellman P, Greiser A, Aletras A . Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012; 33(10):1268-78. PMC: 3350985. DOI: 10.1093/eurheartj/ehr481. View

11.

Cao Y, Xiang L, Qi F, Zhang Y, Chen Y, Zhou X . Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022; 51:101547. PMC: 9284399. DOI: 10.1016/j.eclinm.2022.101547. View

12.

Rowland M, Gallagher C, Gallagher C, Laoide R, Canny G, Marie Broderick A . Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros. 2014; 14(1):120-6. DOI: 10.1016/j.jcf.2014.05.013. View

13.

Debray D, Kelly D, Houwen R, Strandvik B, Colombo C . Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011; 10 Suppl 2:S29-36. DOI: 10.1016/S1569-1993(11)60006-4. View

14.

Boelle P, Debray D, Guillot L, Clement A, Corvol H . Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology. 2018; 69(4):1648-1656. PMC: 6519059. DOI: 10.1002/hep.30148. View

15.

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

16.

Luetkens J, Klein S, Traber F, Block W, Schmeel F, Sprinkart A . Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. Eur Radiol Exp. 2019; 3(1):22. PMC: 6541689. DOI: 10.1186/s41747-019-0100-y. View

17.

Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S . Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol. 2016; 22(32):7236-51. PMC: 4997649. DOI: 10.3748/wjg.v22.i32.7236. View

18.

Kellman P, Wilson J, Xue H, Ugander M, Arai A . Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012; 14:63. PMC: 3441905. DOI: 10.1186/1532-429X-14-63. View

19.

Wang H, Jin K, Zeng M, Chen C, Rao S, Ji Y . Assessing liver fibrosis in chronic hepatitis B using MR extracellular volume measurements: Comparison with serum fibrosis indices. Magn Reson Imaging. 2019; 59:39-45. DOI: 10.1016/j.mri.2019.03.002. View

20.

Rowland M, McGee A, Broderick A, Drumm B, Connolly L, Daly L . Repeatability of transient elastography in children. Pediatr Res. 2020; 88(4):587-592. DOI: 10.1038/s41390-020-0916-4. View